The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patientsImlifidase is an enzyme that rapidly and efficiently cleaves all types of ...

GMT] In this webinar, presented in association with the journal mAbs, Drs. Crescioli and Reichert discuss recent trends in ...

Harbour is eligible for payments of $90m, with potential development and commercial milestones of up to $1.035bn.

("GenSci"), RTW Investments, LP ("RTW"), and Yarrow Bioscience, Inc. ("Yarrow") today announced an exclusive global ex-China license agreement for GS-098, a clinical-stage, first-in-class, humanized ...

Scientists have uncovered a powerful new antibody that disrupts a key protein helping triple-negative breast cancer survive and evade immunity. Triple-negative breast cancer (TNBC) is considered one ...

GOSSELIES, Belgium and NANTES, France, Nov. 12, 2025 /PRNewswire/ -- AbolerIS Pharma ("AbolerIS"), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from ...

-Results highlight the potential to transform treatment of autoimmune diseases, organ transplant rejection and GVHD- GOSSELIES, Belgium and NANTES, France, Nov. 12, 2025 /PRNewswire/ -- AbolerIS ...

The publication can be found online here: Current immunotherapies often suppress the immune system broadly, leading to toxicity and increased infection risk. ABO21009 introduces a novel therapeutic ...

Research led by the University of Washington reports on an AI-guided method that designs epitope-specific antibodies and confirms atomically precise binding using high-resolution molecular imaging, ...

Snakebite envenoming is a neglected tropical disease that affects 1.8 to 2.7 million people worldwide each year, causing 81,000 to 138,000 deaths and 400,000 cases of permanent disability (WHO, 2019).